Published: Dr. Jeffrey Cummings

Dr. Jeffrey Cummings (Brain Health) co-authored “Anti-Tau Trials for Alzheimer’s Disease: A Report from the EU/US/CTAD Task Force,” which explored incorporating tau biomarkers in clinical trials to provide additional knowledge about the potential for treating Alzheimer’s Disease by targeting tau. This represents a new direction in Alzheimer’s Disease therapeutic research. The article appeared in the April issue of the Journal of Prevention of Alzheimer’s Disease.

Cummings also co-authored “Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease,” which concluded the new drug did not improve clinical ratings of dementia among patients with prodromal Alzheimer’s disease, and that cognition and daily function were worse among some patients who received verubecestat compared to those who received the placebo. The trial’s results are making scientists rethink verubecestat as viable in Alzheimer’s Disease treatment. The article appeared in the April issue of The New England Journal of Medicine.

People in the News

People | June 17, 2019
June Cho of UNLV's School of Nursing moved to Las Vegas last year after more than 20 years on the East Coast, eager to discover what life is like in the West.
Closeup of Doris Blackwell
People | June 13, 2019
This program officer I advocates for open communication.
man seated at event listening
People | June 12, 2019
Former UNLV President Don Snyder has played pivotal roles in many key Southern Nevada institutions, including the UNLV School of Medicine